Head-To-Head Comparison: Astellas Pharma (OTCMKTS:ALPMY) versus Acrivon Therapeutics (NASDAQ:ACRV)

Astellas Pharma (OTCMKTS:ALPMY) and Acrivon Therapeutics (NASDAQ:ACRV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Risk & Volatility

Astellas Pharma has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Insider and Institutional Ownership

71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Astellas Pharma and Acrivon Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astellas Pharma	0	0	0	0	0.00
Acrivon Therapeutics	0	0	8	0	3.00

Acrivon Therapeutics has a consensus target price of $23.17, suggesting a potential upside of 934.23%. Given Acrivon Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Astellas Pharma.

Profitability

This table compares Astellas Pharma and Acrivon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Astellas Pharma	-3.10%	13.69%	6.06%
Acrivon Therapeutics	N/A	-47.95%	-43.73%

Earnings & Valuation

This table compares Astellas Pharma and Acrivon Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astellas Pharma	$11.11 billion	1.62	$113.00 million	($0.22)	-45.14
Acrivon Therapeutics	N/A	N/A	-$60.39 million	($2.70)	-0.83

Astellas Pharma has higher revenue and earnings than Acrivon Therapeutics. Astellas Pharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Acrivon Therapeutics beats Astellas Pharma on 8 of the 13 factors compared between the two stocks.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.